Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of ...